No Widgets found in the Sidebar
Gen-2 tACS device shows promising results in clinical study conducted by Nexalin Technology

Mark White, CEO of Nexalin Technology, recently discussed the positive outcomes of a clinical trial involving their Gen-2 tACS device for pain reduction in veteran patients with Mild Traumatic Brain Injury (mTBI). The trial took place at The University of California, San Diego, in collaboration with the United States Department of Veterans Affairs San Diego Healthcare System, as well as various departments at UC San Diego.

mTBI is a pressing issue for both veterans and the general public, resulting in a range of physical, cognitive, emotional, and behavioral challenges. However, effective treatments for post-concussive symptoms (PCS) are scarce, and there is still much to learn about the underlying causes. Symptoms of PCS often overlap with those of post-traumatic stress disorder (PTSD), making diagnosis and treatment even more complex.

The clinical trial was a randomized, double-blind, placebo-controlled study lasting eight weeks. Two groups were involved: an active tACS group and a sham tACS group. Twenty-four veteran patients with mTBI received twelve treatment sessions over four weeks

By Samantha Jones

As a dedicated content writer at, I bring a unique blend of creativity and precision to my work. With a passion for storytelling and a keen eye for detail, I strive to craft engaging and informative articles that captivate our readers. From breaking news to thought-provoking features, I am committed to delivering content that resonates with our audience and keeps them coming back for more. Join me on this exciting journey as we explore the ever-evolving world of news and information together.

Leave a Reply